NVS News and Press, Novartis AG From 02/04/26

Central Garden & Pet Company (CENT) is expected to report $0.11 for Q1 2026 Eli Lilly and Company (LLY) is expected to report $6.99 for Q4 2025 The Ensign Group Inc. (ENSG) is expected to report $1.59 for Q4 2025 McKesson Corporation (MCK) is expected to report $9.31 for Q3 2026 ...

2026-02-04 01:24:20 ET More on Novartis Novartis: Upside Increasingly Capped, 2026 Will Be A Transition Year (Rating Downgrade) Novartis AG (NVS) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Novartis AG (NVS) Presents at 44th Annual J.P. Morg...

2026-02-04 01:05:18 ET More on Novartis Novartis: Upside Increasingly Capped, 2026 Will Be A Transition Year (Rating Downgrade) Novartis AG (NVS) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Novartis AG (NVS) Presents at 44th Annual J.P. Morg...

2026-02-03 19:09:58 ET Novo Nordisk (NYSE:NVO) , a diabetes and obesity drug maker, closed Tuesday at $50.33, down 14.59%. The stock sold off after management projected a 2026 sales and profit decline despite strong recent results, and investors are watching how it defends U.S. obes...

2026-02-03 17:13:10 ET More on the markets How I Use XLB As A Leading Indicator For S&P 500 Kevin Warsh: Hawk, Dove... Or Something Else Entirely? India Dropping Russian Oil Demonstrates How Attractive America's Markets And Economy Are U.S. markets are st...

2026-02-03 11:23:34 ET More on Novartis Novartis: Upside Increasingly Capped, 2026 Will Be A Transition Year (Rating Downgrade) Novartis AG (NVS) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Novartis AG (NVS) Presents at 44th Annual J.P. Morg...

2026-02-02 15:29:07 ET More on pharmaceutical companies Johnson & Johnson: Fraud Claim Dismissal Today Is Not A Sign Talc Litigation Is Over Eli Lilly: Obesity Pricing For Access Tradeoff A Net Positive Johnson & Johnson: Strong Momentum Heading Into 2026 ...

2026-01-29 13:32:23 ET More on related tickers General Motors investing in U.S. workforce to begin production of new vehicles AstraZeneca to invest $15B in China through 2030 Read the full article on Seeking Alpha For further details see: Oakmark Global S...

2026-01-27 18:20:47 ET More on Pfizer, Eli Lilly Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance Pfizer: Expect Another Double Beating For Q1 (Earnings Preview) Eli Lilly: Breakout To New Highs Sends A Clear Warning Shot Healthcare lobbyin...

2026-01-27 05:10:39 ET After a multi-year drought, the iShares Biotechnology ETF ( IBB ) has been quietly having a fantastic run, returning about 28% for 2025, dwarfing its modest returns in 2023, alongside losses in 2022, 2024, amid a renewed risk appetite, a healthy environment of...